EA201691143A1 - Способы лечения гематологических злокачественных опухолей и применение биомаркеров в качестве показателя клинической чувствительности к иммуномодулирующей терапии - Google Patents
Способы лечения гематологических злокачественных опухолей и применение биомаркеров в качестве показателя клинической чувствительности к иммуномодулирующей терапииInfo
- Publication number
- EA201691143A1 EA201691143A1 EA201691143A EA201691143A EA201691143A1 EA 201691143 A1 EA201691143 A1 EA 201691143A1 EA 201691143 A EA201691143 A EA 201691143A EA 201691143 A EA201691143 A EA 201691143A EA 201691143 A1 EA201691143 A1 EA 201691143A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- biomarkers
- treatment
- methods
- malignant tumors
- indicator
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title abstract 2
- 230000002489 hematologic effect Effects 0.000 title abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000035945 sensitivity Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 abstract 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960004942 lenalidomide Drugs 0.000 abstract 1
- 229940120975 revlimid Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913046P | 2013-12-06 | 2013-12-06 | |
| PCT/US2014/068767 WO2015085160A2 (en) | 2013-12-06 | 2014-12-05 | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201691143A1 true EA201691143A1 (ru) | 2016-11-30 |
Family
ID=53274284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691143A EA201691143A1 (ru) | 2013-12-06 | 2014-12-05 | Способы лечения гематологических злокачественных опухолей и применение биомаркеров в качестве показателя клинической чувствительности к иммуномодулирующей терапии |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160312292A1 (enExample) |
| EP (1) | EP3077547A4 (enExample) |
| JP (1) | JP2017503481A (enExample) |
| KR (1) | KR20160090390A (enExample) |
| AU (1) | AU2014360316A1 (enExample) |
| BR (1) | BR112016012792A2 (enExample) |
| CA (1) | CA2932266A1 (enExample) |
| EA (1) | EA201691143A1 (enExample) |
| IL (1) | IL245936A0 (enExample) |
| MX (1) | MX2016007179A (enExample) |
| PH (1) | PH12016501023A1 (enExample) |
| WO (1) | WO2015085160A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160282354A1 (en) | 2013-11-08 | 2016-09-29 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| EA201691144A1 (ru) | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| EP3996039A1 (en) * | 2014-10-17 | 2022-05-11 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Image analysis method supporting illness development prediction for a neoplasm in a human or animal body |
| US10338077B2 (en) | 2015-06-02 | 2019-07-02 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins |
| US11459613B2 (en) | 2015-09-11 | 2022-10-04 | The Brigham And Women's Hospital, Inc. | Methods of characterizing resistance to modulators of Cereblon |
| JP2018529344A (ja) * | 2015-09-25 | 2018-10-11 | セルジーン コーポレイション | びまん性大細胞型ｂ細胞リンパ腫の治療方法及び薬物に対する応答性の予測因子としてのバイオマーカー利用 |
| US10648983B2 (en) | 2016-01-08 | 2020-05-12 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| JP7357921B2 (ja) * | 2017-09-29 | 2023-10-10 | 国立大学法人九州大学 | びまん性大細胞型ｂ細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット |
| AU2020372333A1 (en) * | 2019-10-21 | 2022-04-28 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| WO2024258819A1 (en) * | 2023-06-15 | 2024-12-19 | The Broad Institute, Inc. | Neoplastic cytotoxicity induced by glycosylation |
| FR3158740A1 (fr) * | 2024-01-30 | 2025-08-01 | Universite Grenoble Alpes | Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009085234A2 (en) * | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| EP2544687A1 (en) * | 2010-03-12 | 2013-01-16 | Celgene Corporation | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
-
2014
- 2014-12-05 MX MX2016007179A patent/MX2016007179A/es unknown
- 2014-12-05 US US15/101,866 patent/US20160312292A1/en not_active Abandoned
- 2014-12-05 EP EP14867978.0A patent/EP3077547A4/en not_active Withdrawn
- 2014-12-05 KR KR1020167017539A patent/KR20160090390A/ko not_active Withdrawn
- 2014-12-05 BR BR112016012792A patent/BR112016012792A2/pt not_active Application Discontinuation
- 2014-12-05 EA EA201691143A patent/EA201691143A1/ru unknown
- 2014-12-05 AU AU2014360316A patent/AU2014360316A1/en not_active Abandoned
- 2014-12-05 WO PCT/US2014/068767 patent/WO2015085160A2/en not_active Ceased
- 2014-12-05 JP JP2016536527A patent/JP2017503481A/ja active Pending
- 2014-12-05 CA CA2932266A patent/CA2932266A1/en not_active Abandoned
-
2016
- 2016-05-31 PH PH12016501023A patent/PH12016501023A1/en unknown
- 2016-05-31 IL IL245936A patent/IL245936A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016012792A2 (pt) | 2017-08-08 |
| WO2015085160A3 (en) | 2015-07-30 |
| PH12016501023A1 (en) | 2016-07-04 |
| US20160312292A1 (en) | 2016-10-27 |
| KR20160090390A (ko) | 2016-07-29 |
| MX2016007179A (es) | 2016-09-08 |
| EP3077547A2 (en) | 2016-10-12 |
| CA2932266A1 (en) | 2015-06-11 |
| AU2014360316A1 (en) | 2016-06-16 |
| IL245936A0 (en) | 2016-07-31 |
| EP3077547A4 (en) | 2017-11-08 |
| WO2015085160A2 (en) | 2015-06-11 |
| JP2017503481A (ja) | 2017-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691143A1 (ru) | Способы лечения гематологических злокачественных опухолей и применение биомаркеров в качестве показателя клинической чувствительности к иммуномодулирующей терапии | |
| IL260774B (en) | Preparations containing 3cd19 x cd bispecific antibodies for the treatment of tumors of lymph node tissue and/or extra-lymph node lymphoma as a result of diffuse large b-cell lymphoma (dlbcl) | |
| MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| SA521430032B1 (ar) | Vista أجسام مضادة لـ وأجزاء منها | |
| BR112015007184A2 (pt) | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer | |
| MX2021007790A (es) | Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
| MX2021002728A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
| MX2021006895A (es) | Acidos nucleicos libres de celulas para el analisis del microbioma humano y componentes del mismo. | |
| EP2209495A4 (en) | TAZ / WWTR1 FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| BR112015022934A2 (pt) | esteroides neuroativos, composições, e uso do mesmo | |
| MY196631A (en) | Antibody Agents Specific for Human Cd19 and uses Thereof | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| EA201201081A1 (ru) | Производные гетарил[1,8]нафтиридина | |
| EA201491574A1 (ru) | Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car | |
| WO2009075797A3 (en) | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma | |
| WO2017024019A8 (en) | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| EP2968470A4 (en) | MODIFIED PROTEINS WITH A MÜLLERSCHEN HEMMERSUBSTANZ AND USES THEREOF FOR THE TREATMENT OF DISEASES | |
| MX2020002216A (es) | Metodos y composiciones para detectar y tratar endometriosis. | |
| JP2017503481A5 (enExample) | ||
| MX2017006537A (es) | Anticuerpos contra metabolitos de serotonina, triptofano y cinurenina, y usos de los mismos. | |
| EA201591399A1 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| EA201691682A1 (ru) | Способы анализирования редких циркулирующих в крови клеток | |
| MX2018003697A (es) | Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos. |